GALNS and mucopolysaccharidosis type 4A: The therapeutic benefit resulted from AAV9-Galns vector-mediated widespread biodistribution after intravascular administration, together with the use of the ubiquitous CAG promoter that enabled the local increase of Galns expression in the main peripheral tissues affected in MPSIVA disease.